Advice

Following an abbreviated submission

insulin glulisine 100 units/ml solution for injection in a pre-filled pen (Apidra Solostar) is accepted for restricted use within NHS Scotland for the treatment of adult patients with diabetes mellitus in whom treatment with this insulin analogue is appropriate and in whom the use of a pre-filled pen offers advantages over a pen and cartridge device.

Insulin glulisine has similar efficacy to other short-acting insulins in reducing glycated haemoglobin and a similar pharmacokinetic profile to at least one other insulin analogue. It is restricted to use in patients where regular human insulin is inappropriate.

Download detailed advice57KB (PDF)

Download

Medicine details

Medicine name:
insulin glulisine (Apidra Solostar)
SMC ID:
457/08
Indication:
Treatment of adult patients with diabetes mellitus
Pharmaceutical company
Sanofi-Aventis
BNF chapter
Endocrine system
Submission type
Abbreviated
Status
Restricted
Date advice published
07 April 2008